Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24675514 | 1.00 | CA12 (0.41) | CA12CA1CA2CA9PDE3B | |
| SCHEMBL24675640 | 0.89 | CA12 (0.40) | CA12CA1CA2CA9PDE3B | |
| SCHEMBL29823274 | 0.89 | CA12 (0.40) | CA12CA1CA2CA9PDE3B | |
| SCHEMBL30490969 | 0.87 | CA12 (0.42) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL24675738 | 0.87 | CA12 (0.42) | CA12CA1CA2CA9PDK2 | |
| SCHEMBL25289842 | 0.82 | GLS (0.46) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL30490889 | 0.82 | GLS (0.46) | CA12CA1CA2CA9CNR2 | |
| SCHEMBL24675148 | 0.81 | PDE3B (0.44) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675802 | 0.81 | PDE3B (0.38) | CA12CA1CA2CA9PDE3B | |
| SCHEMBL24675790 | 0.81 | PDE3B (0.38) | CA12CA1CA2CA9PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129564-A9 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4281445-A1 | DEGRADERS OF GRK2 AND USES THEREOF | Sonata Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023129564-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |